Older age (≥60 years)1-3
While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalisation and death, particularly in older adults and those with underlying conditions1
A large prospective study estimated the incidence of RSV-associated hospitalisation in two regions of New York State, USA, 2017–2020. N=1099 cases:2
Comorbidity | Incidence rate ratio* | |
---|---|---|
Rochester |
NYC | |
COPD | ||
50-64y |
6.35 |
6.30 |
≥65y |
13.41 |
3.51 |
Asthma |
||
50-64y | 2.34 | 3.60 |
≥65y | 2.52 | 2.27 |
Diabetes | ||
50-64y | 3.36 | 3.58 |
≥65y | 6.44 | 2.35 |
CAD | ||
50-64y | 3.74 | 4.41 |
≥65y | 6.46 | 3.75 |
CHF | ||
60-79y | 7.63 | 5.86 |
≥80y | 3.99 | 5.40 |
In older adults hospitalised with RSV, the risk of severe outcomes is comparable to those hospitalised with influenza
CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NYC, New York City; RSV, respiratory syncytial virus
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
©2023 GSK group of companies. All rights reserved.
July 2024 | NX-GB-GVU-WCNT-230008 (V2.0)